Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to TKA

The study is single center, prospective, randomized, controlled trial to include 50 subjects,
25 treated with Regenexx SD and 25 treated with Exercise Therapy for treatment of knee
osteoarthritis. Subjects will be enrolled within 60 days prior to Regenexx-SD injection or
initiation of Exercise Therapy and take part in follow-up visits for two years following
treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will
occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post
injection.

Subjects in the control, exercise therapy arm, will have the opportunity to cross-over to the
study treatment arm at or after the 3 month visit and then continue to be followed through 24
months.

Subjects will complete the study following the 2 year follow-up visit. They will be withdrawn
from the study prematurely if a revision occurs.

The study subjects will be compared to a historical total knee arthroplasty group. Data of
the TKA group subjects will be reviewed retrospectively after it is retrieved from the
clinical database. The TKA group will consist of patients who underwent TKA for knee
osteoarthritis. The inclusion criteria of age and BMI will be applied to these subjects.

Inclusion Criteria:

1. Voluntary signature of the IRB approved Informed Consent

2. Ages 18 to 70

3. Diagnosis of Knee osteoarthritis

4. Kellgren-Lawrence Grade 2 or 3 on X-Ray

5. BMI of <30

6. Minimum flexion to 110 degrees

7. Varus under 12 degrees/Valgus under 15 degrees

8. Instability in any plane less than 2 mm translation

9. ACL intact and no history of ACL reconstruction

10. Knee Society 100 point score > 65

11. If bilateral arthritis, subject must be able and willing to delay treatment of the
second side for at least 6 months

12. Candidate is able to follow Regenexx medication guidelines

13. Patient agrees to return for periodic assessment protocol

14. Patient must execute all required documents

15. Patient must be appraised of Clinical Trial

Exclusion Criteria:

1. History of infection of the joint in the last five years

2. Intra-articular PRP, steroid or viscosupplementation in the last three months

3. Previous knee surgery within the last 6 months

4. Flexion contracture over 15 degrees

5. Low back pain with radiculopathy or with "significant" radiographic changes

6. History of immunosuppressive or chemotherapy in the last five years

7. Systemic neurological disease

8. HIV positive or chronic hepatitis

9. Any significant co-morbidity that in the opinion of the investigator should exclude
the subject from the study